LAVA Therapeutics N.V. 4PKB.F Stock
LAVA Therapeutics N.V. Price Chart
LAVA Therapeutics N.V. 4PKB.F Financial and Trading Overview
LAVA Therapeutics N.V. stock price | 1.76 EUR |
Previous Close | 1.77 EUR |
Open | 1.75 EUR |
Bid | 1.85 EUR x N/A |
Ask | 1.92 EUR x N/A |
Day's Range | 1.75 - 1.75 EUR |
52 Week Range | 1.27 - 6.8 EUR |
Volume | 3.4K EUR |
Avg. Volume | 116 EUR |
Market Cap | 46.01M EUR |
Beta (5Y Monthly) | -0.505886 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.04 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23 EUR |
4PKB.F Valuation Measures
Enterprise Value | -71919320 EUR |
Trailing P/E | N/A |
Forward P/E | -0.9114584 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.3480797 |
Price/Book (mrq) | 0.61124694 |
Enterprise Value/Revenue | -3.671 |
Enterprise Value/EBITDA | 1.937 |
Trading Information
LAVA Therapeutics N.V. Stock Price History
Beta (5Y Monthly) | -0.505886 |
52-Week Change | -12.83% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.8 EUR |
52 Week Low | 1.27 EUR |
50-Day Moving Average | 1.62 EUR |
200-Day Moving Average | 2.99 EUR |
4PKB.F Share Statistics
Avg. Volume (3 month) | 116 EUR |
Avg. Daily Volume (10-Days) | 653 EUR |
Shares Outstanding | 26.29M |
Float | 8.04M |
Short Ratio | N/A |
% Held by Insiders | 28.58% |
% Held by Institutions | 45.71% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -183.86% |
Operating Margin (ttm) | -192.23% |
Gross Margin | -109.43% |
EBITDA Margin | -189.52% |
Management Effectiveness
Return on Assets (ttm) | -17.78% |
Return on Equity (ttm) | -39.22% |
Income Statement
Revenue (ttm) | 19.59M EUR |
Revenue Per Share (ttm) | 0.75 EUR |
Quarterly Revenue Growth (yoy) | 19.80% |
Gross Profit (ttm) | -20714000 EUR |
EBITDA | -37133000 EUR |
Net Income Avi to Common (ttm) | -36025000 EUR |
Diluted EPS (ttm) | -1.19 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 125.43M EUR |
Total Cash Per Share (mrq) | 4.77 EUR |
Total Debt (mrq) | 6.98M EUR |
Total Debt/Equity (mrq) | 9.28 EUR |
Current Ratio (mrq) | 5.54 |
Book Value Per Share (mrq) | 2.863 |
Cash Flow Statement
Operating Cash Flow (ttm) | 3.34M EUR |
Levered Free Cash Flow (ttm) | -20328624 EUR |
Profile of LAVA Therapeutics N.V.
Country | Germany |
State | N/A |
City | Utrecht |
Address | Yalelaan 60 |
ZIP | 3584 CM |
Phone | 31 630 00 30 35 |
Website | https://www.lavatherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 69 |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Q&A For LAVA Therapeutics N.V. Stock
What is a current 4PKB.F stock price?
LAVA Therapeutics N.V. 4PKB.F stock price today per share is 1.76 EUR.
How to purchase LAVA Therapeutics N.V. stock?
You can buy 4PKB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for LAVA Therapeutics N.V.?
The stock symbol or ticker of LAVA Therapeutics N.V. is 4PKB.F.
Which industry does the LAVA Therapeutics N.V. company belong to?
The LAVA Therapeutics N.V. industry is Biotechnology.
How many shares does LAVA Therapeutics N.V. have in circulation?
The max supply of LAVA Therapeutics N.V. shares is 26.86M.
What is LAVA Therapeutics N.V. Price to Earnings Ratio (PE Ratio)?
LAVA Therapeutics N.V. PE Ratio is now.
What was LAVA Therapeutics N.V. earnings per share over the trailing 12 months (TTM)?
LAVA Therapeutics N.V. EPS is -1.04 EUR over the trailing 12 months.
Which sector does the LAVA Therapeutics N.V. company belong to?
The LAVA Therapeutics N.V. sector is Healthcare.